In this online, self-learning activity:
Prostate cancer is the most common form of malignancy among men in the United States.There are over 164,600 new cases and over 29,000 deaths from PC in the U.S. annually. Probable risk factors include age 65 and older, African American ancestry, family history, and mutations in the BRCA1, -2, MSH2, and HOXB13 genes, with possible risk factors including occupational exposure to cadmium, dietary factors, and higher concentrations of serum testosterone. About 95% of cases are adenocarcinoma, with neuroendocrine tumors, sarcomas, and transitional cell carcinomas comprising the balance of tumor types. Symptoms of advanced prostate cancer (aPC) include back pain, cord compression, lower extremity edema, pathologic fractures, anemia, and weight loss.
The following HCPs: oncologists and urologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and any other HCPs with an interest in or who may clinically encounter patients with aPC.
Commercial Support Disclosure: This program is supported by educational grants from Sanofi / Genzyme.
This activity is free of charge.
Release Date: May 05, 2019 -- Expiration Date: May 05, 2021
Faculty: David Wise, MD
Treatment in patients with aPC
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
David Wise, M.D., Attending Medical Oncologist, Genitourinary Cancers Program, Perlmutter Cancer Center at NYU, discloses that he has received research or speakers bureau funding from Foundation Medicine, LEAP Therapeutics, Best Doctors, Guidepoint, and GLG.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial discloses.
Commercial Support Disclosure: This program is supported by educational grants from Sanofi / Genzyme
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Addressing skeletal-related events in prostate cancer
Advanced prostate cancer: Optimizing management strategies
Ovarian Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments